CALT: חוב לטווח קצר של החברה Calliditas Therapeutics, Inc.

Calliditas Therapeutics focuses on the therapy of rare nephrological pathologies, capturing an extensive market due to the absence of viable alternatives. Current cash flow is generated by the global sales of Tarpeyo, which confirms the trajectory of the market capitalization, where the figure stands at 0.00. The company's high authority among physicians is driven by the creation of an innovative method that addresses the root cause of the disease and prevents the need for dialysis.

This indicator captures the total liabilities with a maturity of up to one year, allowing for an assessment of current liquidity and the risk of working capital shortages. By analyzing the company's short-term loans and borrowings, an investor can track the borrowing trends required by Calliditas Therapeutics (CALT) to fund the development and commercialization of drugs for renal failure, which is critical given the high capital intensity of the pharmaceutical business.